2. Search Result
Search Result
Results for "

GPR55

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Natural
Products

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16697
    CID 16020046
    1 Publications Verification

    		 GPR55 Cancer
    CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM. CID 16020046 inhibits GPR55-mediated Ca 2+ signaling and GPR55-mediated ERK1/2 phosphorylation. CID 16020046 reduces wound healing in endothelial cells and is involved in the regulation of platelet function .
    CID 16020046
  • HY-125111
    PSB-SB-487

    		GPR55 Cannabinoid Receptor Neurological Disease Metabolic Disease Cancer
    PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer .
    PSB-SB-487
  • HY-110125
    ML-193

    CID 1261822

    		 GPR55 Neurological Disease
    ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
    ML-193
  • HY-111083
    ML191

    CID23612552

    		 GPR55 Others
    ML-191 is an antagonist of GPR55. It inhibits GPR55 signaling induced by lysophosphatidylinositol (EC50=1.076 µM in U2OS cells overexpressing GPR55). ML-191 inhibits LPI-induced phosphorylation of ERK1/2 (IC50=328 nM) and receptor-dependent translocation of PKCβII when used at a concentration of 30 µM .
    ML191
  • HY-156157
    GPR55 agonist 4

    		GPR55 Cancer
    GPR55 agonist 4 (Compound 28) is a GPR55 agonist (EC50: 131 nM, and 1.41 nM for hGPR55 and rGPR55). GPR55 agonist 4 induces β-arrestin recruitment to human GPR55 .
    GPR55 agonist 4
  • HY-156107
    GPR55 agonist 3

    		GPR55 Cancer
    GPR55 agonist 3 (Compound 26) is a GPR55 agonist (EC50: 0.239 nM, and 1.76 nM for hGPR55 and rGPR55). GPR55 agonist 3 induces β-arrestin recruitment to human GPR55 (EC50: 6.2 nM) .
    GPR55 agonist 3
  • HY-RS05721
    GPR55 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    GPR55 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR55 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GPR55 Human Pre-designed siRNA Set A
    GPR55 Human Pre-designed siRNA Set A
  • HY-RS05722
    Gpr55 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gpr55 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gpr55 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gpr55 Mouse Pre-designed siRNA Set A
    Gpr55 Mouse Pre-designed siRNA Set A
  • HY-RS05723
    Gpr55 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Gpr55 Rat Pre-designed siRNA Set A contains three designed siRNAs for Gpr55 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Gpr55 Rat Pre-designed siRNA Set A
    Gpr55 Rat Pre-designed siRNA Set A
  • HY-123302
    CID1172084

    		GPR55 Neurological Disease
    CID1172084 (compound 3) is a selective GPR55 agonist (EC50=0.16 μM). CID1172084 is more than 100-fold selective for GPR55 over GPR35, CB1, and CB2. CID1172084 can be used to further explore the biological functions and signaling pathways of the GPR55 receptor .
    CID1172084
  • HY-116637
    Tetrahydromagnolol

    Magnolignan

    		 Cannabinoid Receptor GPR55 Inflammation/Immunology
    Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective cannabinoid CB2 receptor agonist with an EC50 of 170 nM and a Ki of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist .
    Tetrahydromagnolol
  • HY-114954
    CID1792197

    		GPR55 Neurological Disease Inflammation/Immunology
    CID1792197 is a GPR55 agonist with an EC50 value of 0.11 μM .
    CID1792197
  • HY-116461
    ML-184

    CID2440433

    		 GPR55 Neurological Disease
    ML-184 (CID2440433) is a selective GPR55 agonist with an EC50 of 250 nM and exhibits >100-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-184 induces phosphorylation of ERK1/2 and translocation of PKCβII to the plasma membrane by activating GPR55 . ML-184(CID2440433) increases proliferation of neural stem cells and promotes neuronal differentiation in vitro .
    ML-184
  • HY-111162
    GSK494581A

    		GPR55 GlyT Cardiovascular Disease Neurological Disease
    GSK494581A is a specific ligand for human GPR55 (pEC50 of 6.8) and also acts as an inhibitor of glycine transporter subtype 1 (GlyT1). GSK494581A may regulate pain signaling, bone morphogenesis, and vascular endothelial cell formation by binding to GPR55 .
    GSK494581A
  • HY-103336
    Tocrifluor 1117

    T1117

    		 GPR55 Cannabinoid Receptor Cardiovascular Disease
    Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .
    Tocrifluor 1117
  • HY-107536
    ML 145
    1 Publications Verification

    		 GPR35 CXCR Inflammation/Immunology Endocrinology
    ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
    ML 145
  • HY-W020035
    L-α-lysophosphatidylinositol (Soy) (sodium)

    		GPR55 Neurological Disease
    L-α-lysophosphatidylinositol Soy sodium is an endogenous ligand of GPR55. L-α-lysophosphatidylinositol Soy sodium is an endogenous lysophospholipid and endocannabinoid neurotransmitter that belongs to the class of lysophospholipids .
    L-α-lysophosphatidylinositol (Soy) (sodium)
  • HY-122246
    ML192

    		GPR55 PKC ERK Arrestin Metabolic Disease
    ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocation .
    ML192
  • HY-15443
    AM251
    Maximum Cited Publications
    18 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM .
    AM251
  • HY-123239
    KLS-13019

    		GPR55 Neurological Disease
    KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats .
    KLS-13019
  • HY-162618
    PSB-KK1445

    		Cannabinoid Receptor Neurological Disease
    PSB-KK1445 is a potent and selective GPR18 agonist with EC50s of 45.4 nM and 124 nM for human and mouse GPR18, respectively. PSB-KK1445 displays >200-fold selectivity versus both CB receptor subtypes, GPR55, and GPR183 .
    PSB-KK1445
  • HY-107541
    O-1602
    2 Publications Verification

    		 GPR55 Neurological Disease
    O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602
  • HY-107541R
    O-1602 (Standard)

    		GPR55 Neurological Disease
    O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: